# Does Vascular Endothelial Growth Factor (VEGF) or Complement Factor H Gene Polymorphism Play a Role in the Treatment Success With VEGF Inhibitors in Patients With Choroidal NeoVascularization (CNV)?

> **NCT00813514** · NA · WITHDRAWN · sponsor: **Medical University of Vienna**

## Conditions studied

- Choroidal NeoVascularization
- Age-Related Macular Degeneration

## Interventions

- **GENETIC:** VEGF genotyping

## Key facts

- **NCT ID:** NCT00813514
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-01
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2014-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00813514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00813514, "Does Vascular Endothelial Growth Factor (VEGF) or Complement Factor H Gene Polymorphism Play a Role in the Treatment Success With VEGF Inhibitors in Patients With Choroidal NeoVascularization (CNV)?". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00813514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*